Skip to nav Skip to content
Nagi  Kumar

Nagi Kumar, PhD, RD, FADA

Program: Cancer Epidemiology

Research Program: Cancer Epidemiology Program


  • Overview

    Dr. Kumar is a Senior Member of the Cancer Epidemiology, Genitourinary and Breast Oncology Departments at the Moffitt Cancer Center.  She collaborates with investigators in basic, population, and clinical sciences, both nationally and internationally, and has developed a program to accelerate agent development and biomarker validation for cancer chemoprevention. 


    • Cancer Epidemiology
    • Genitourinary Oncology
    • Breast Oncology
    • Cancer Epidemiology Program
    • Cancer Chemoprevention Research Interest Group

    Education & Training


    • University of South Florida, Tampa, Florida, MA - Adult Education
    • University of South Florida, Tampa, Florida, PhD - Interdisciplinary Studies, Applied Behavior Analysis & Public Health Nutrition


    • City Hospital Center at Elmhurst, Mt. Sinai School of Medicine, New York - Intern - Dietetic
  • Research Interest

    Using a multi-disciplinary science-based approach and the rigor with which other therapeutic agents are tested, Dr. Kumar has initiated several epidemiological, laboratory, preclinical and phase I-II clinical trials evaluating safety, effectiveness and potential molecular targets of several agents for cancer chemoprevention, including green tea catechins, isoflavones, tannic acid, n-3 fatty acids, metformin, anthocyanins, sulforaphanes, Quercetin, n-3 fatty acids, curcumin, and combination agents for cancer chemoprevention.  She leads two active phase II secondary chemoprevention trials targeting men with localized prostate cancer. Informed by her laboratory and early phase clinical trials, the goal of these randomized clinical trials is to comprehensively and rigorously evaluate the safety, effectiveness, and mechanism of green tea catechins on clinical and biological intermediate endpoint markers, implicated in prostate carcinogenesis, that will ultimately inform development of Phase III clinical trials for secondary chemoprevention of prostate cancer in men on active surveillance. And these trials will create a specimen repository with which to test future and evolving novel hypotheses to assess other genetic or environmental factors that may influence incidence and progression of prostate cancer.  Dr. Kumar also leads a phase II chemoprevention trial evaluating a combination of curcumin and n-3 fatty acids to modulate lung nodules in former smokers.  And she has developed and tested multimodal interventions to characterize and ameliorate symptoms of cancer treatment including for hypothyroidism, cancer cachexia, and cognitive impairment.  Her goal for cancer chemoprevention at Moffitt Cancer Center is to utilize a systematic, broad spectrum approach to identify agents that can: (a) produce robust and concurrent inhibition of multiple hallmark-associated pathways in target (precursor or early stage tumor) tissue/microenvironment, (b) addressing the underlying biology of carcinogenesis; (c) enhance bioavailability and half-life, (d) with minimum toxicity, (e) in exceptionally high risk populations.

  • Participating Trials

    Clinical Trial 19622
    Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers
    Condition: Thoracic
    Intervention: Curcumin C3 (); Lovaza (); Placebo ()
    Status: Open

    Clinical Trial 20056
    Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
    Condition: Genitourinary
    Intervention: Sunphenon 90D/placebo ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Johansson H, Guerrieri-Gonzaga A, Gandini S, Bertelsen BE, Macis D, Serrano D, Mellgren G, Lazzeroni M, Thomas PS, Crew KD, Kumar NB, Briata IM, Galimberti V, Viale G, Vornik LA, Aristarco V, Buttiron Webber T, Spinaci S, Brown PH, Heckman-Stoddard BM, Szabo E, Bonanni B, DeCensi A. Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. NPJ Breast Cancer. 2024 Jan.10(1):7. Pubmedid: 38238336. Pmcid: PMC10796398.
    • Serrano D, Gandini S, Thomas P, Crew KD, Kumar NB, Vornik LA, Lee JJ, Veronesi P, Viale G, Guerrieri-Gonzaga A, Lazzeroni M, Johansson H, D'Amico M, Guasone F, Spinaci S, Bertelsen BE, Mellgren G, Bedrosian I, Weber D, Castile T, Dimond E, Heckman-Stoddard BM, Szabo E, Brown PH, DeCensi A, Bonanni B. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023 May.9(5):664-672. Pubmedid: 36951827. Pmcid: PMC10037202.
    • Kumar NB, Bahl S, Dhillon J, Poch M, Manley B, Li R, Schell M, Powsang J. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials. Cancers (Basel). 2023 Feb.15(4). Pubmedid: 36831597. Pmcid: PMC9954186.
    • Carastro LM, Vallebuona EJ, Cordova R, Gannon AN, Kim SJ, Costello CM, Declet-Bauzo RA, Kumar N, Park JY. Polyphenon E Effects on Gene Expression in PC-3 Prostate Cancer Cells. Int J Mol Sci. 2022 Nov.23(22). Pubmedid: 36430806. Pmcid: PMC9697490.
    • Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, Dhillon J, Yu A, Byrd DA. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome. Cancers (Basel). 2022 Aug.14(16). Pubmedid: 36010981. Pmcid: PMC9406482.
    • Zachariah NN, Basu A, Gautam N, Ramamoorthi G, Kodumudi KN, Kumar NB, Loftus L, Czerniecki BJ. Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. Front Immunol. 2021 Nov.12:786286. Pubmedid: 34899753. Pmcid: PMC8652247.
    • Kumar NB. The Promise of Nutrient-Derived Bioactive Compounds and Dietary Components to Ameliorate Symptoms of Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors. CURR TREAT OPTION ON. 2021 Jun.22(8):67. Pubmedid: 34110516.
    • Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671939. Pmcid: PMC7919015.
    • Guerrieri-Gonzaga A, Serrano D, Thomas P, Crew KD, Kumar NB, Gandini S, Vornik LA, Lee J, Cagnacci S, Vicini E, Accornero CA, D'Amico M, Guasone F, Spinaci S, Webber TB, Brown PH, Szabo E, Heckman-Stoddard B, Bonanni B. Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemp Clin Trials. 2021 Aug.107:106498. Pubmedid: 34216815. Pmcid: PMC8429140.
    • Kumar NB. Does COVID-19-related cachexia mimic cancer-related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management. J Cachexia Sarcopenia Muscle. 2021 Apr.12(2):519-522. Pubmedid: 33554483. Pmcid: PMC8013485.
    • Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
    • Ganguly A, Frank D, Kumar N, Cheng YC, Chu E. Cancer Biomarkers for Integrative Oncology. Curr Oncol Rep. 2019 Mar.21(4):32. Pubmedid: 30834992.
    • Permuth JB, Clark Daly A, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li J, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. Cancer Med. 2019 Jun.8(6):3314-3324. Pubmedid: 31074202. Pmcid: PMC6558500.
    • Poff A, Kourtnik A, Egan KM, Sahebjum S, D'Agostino D, Kumar NB. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Semin Cancer Biol. 2019 Jun.56:135-148. Pubmedid: 29294371. Pmcid: PMC6927557.
    • Bagde A, Patel K, Mondal A, Kutlehria S, Chowdhury N, Gebeyehu A, Patel N, Kumar N, Singh M. Combination of UVB Absorbing Titanium Dioxide and Quercetin Nanogel for Skin Cancer Chemoprevention. AAPS PharmSciTech. 2019 Jun.20(6):240. Pubmedid: 31250221.
    • Handing EP, Small BJ, Andel R, McEvoy CL, Kumar N. Can Nutrition or Inflammation Moderate the Age-Cognition Association Among Older Adults?. J Gerontol B Psychol Sci Soc Sci. 2019 Jan.74(2):193-201. Pubmedid: 28482093.
    • White JD, O'Keefe BR, Sharma J, Javed G, Nukala V, Ganguly A, Khan IA, Kumar NB, Mukhtar H, Pauli GF, Walker L, Sivaram S, Rajaraman P, Trimble EL. India-United States Dialogue on Traditional Medicine: Toward Collaborative Research and Generation of an Evidence Base. J Glob Oncol. 2018 Sep.4:1-10. Pubmedid: 30241135. Pmcid: PMC6180779.
    • Kumar NB, Fink A, Levis S, Xu P, Tamura R, Krischer J. Thyroid function in the etiology of fatigue in breast cancer. Oncotarget. 2018 May.9(39):25723-25737. Pubmedid: 29876020. Pmcid: PMC5986636.
    • Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec.9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
    • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Nov.8(58):99093-99103. Pubmedid: 29228755. Pmcid: PMC5716795.
    • Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May.8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
    • Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017 Mar.17(1):18. Pubmedid: 28320379. Pmcid: PMC5359825.
    • White JD, Lin H, Jia L, Wu RS, Lam S, Li J, Dou J, Kumar N, Lin L, Lao L. Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer. J Glob Oncol. 2017 Dec.3(6):814-822. Pubmedid: 29244995. Pmcid: PMC5735960.
    • Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM. Chemoprevention in African American Men With Prostate Cancer. Cancer Control. 2016 Oct.23(4):415-423. Pubmedid: 27842331.
    • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct.7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
    • Pietro GD, Chornokur G, Kumar NB, Davis C, Park JY. Racial Differences in the Diagnosis and Treatment of Prostate Cancer. Int Neurourol J. 2016 Nov.20(Suppl 2):S112-S119. Pubmedid: 27915474. Pmcid: PMC5169094.
    • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
    • Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015 Dec.35 Suppl:S78-S103. Pubmedid: 25936818. Pmcid: PMC4720504.
    • Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, ...
    • Handing EP, Small BJ, Reynolds SL, Kumar NB. Impact of Dietary Factors and Inflammation on Cognition among Older Adults. J Prev Alzheimers Dis. 2015.2(4):220-226. Pubmedid: 29219165.
    • Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep.4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
    • Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB. Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2014 Jan.2013:384594. Pubmedid: 24386569. Pmcid: PMC3872424.
    • Kim S, Amankwah EK, Connors S, Park HY, Rincon M, Cornnell HH, Chornokur G, Ibrahim-Hashim A, Choi J, Tsai YY, Engelman R, Kumar NB, Park JY. Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila). 2014 Apr.7(4):435-444. Pubmedid: 24501325. Pmcid: PMC4123218.
    • Green BL, Rivers DA, Kumar N, Baldwin J, Rivers BM, Sultan D, Jacobsen P, Gordon LE, Davis J, Roetzheim R. Establishing the infrastructure to comprehensively address cancer disparities: a model for transdisciplinary approaches. J Health Care Poor Underserved. 2013 Nov.24(4):1614-1623. Pubmedid: 24185157. Pmcid: PMC4163783.
    • Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, Pietanza MC, Cassileth BR. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May.143(5 Suppl):e420S-e436S. Pubmedid: 23649450.
    • Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Deng G, Djeu J, Dou J, Hawk E, Jayaram B, Jia L, Joshi R, Kararala M, Karunagaran D, Kucuk O, Kumar L, Malafa M, Samathanam GJ, Sarkar F, Siddiqi M, Singh RP, Srivastava A, White JD. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med. 2013 Feb.2(1):108-115. Pubmedid: 24279005. Pmcid: PMC3797562.
    • Chornokur G, Kumar NB. Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control. 2013 Aug.24(8):1465-1480. Pubmedid: 23737026. Pmcid: PMC4184029.
    • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep.21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
    • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar.2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
    • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar.33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
    • Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet. 2012 Jun.1(2). Pubmedid: 26097796. Pmcid: PMC4474476.
    • Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer. 2012 Jul.64(1):4-22. Pubmedid: 22098273. Pmcid: PMC3665011.
    • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan.2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
    • Kumar N, Chornokur G. Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale). 2012 Dec.Suppl 2:005. Pubmedid: 24527269. Pmcid: PMC3920581.
    • Ribeiro MdLC, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Arig IH, Gillies RJ. Buffer Therapy for Cancer. J Nutr Food Sci. 2012 Aug.2:6. Pubmedid: 24371544. Pmcid: PMC3872072.
    • Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011 Jun.71(9):985-997. Pubmedid: 21541975. Pmcid: PMC3083484.
    • Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs. 2011 Feb.15(1):63-71. Pubmedid: 21278042.
    • Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. CURR TREAT OPTION ON. 2010 Dec.11(3-4):107-117. Pubmedid: 21128029. Pmcid: PMC3016925.
    • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010.8(1):3-13. Pubmedid: 20205984. Pmcid: PMC3277948.
    • Kumar NB, Yu D, Akinremi TO, Odedina FT. Comparing dietary and other lifestyle factors among immigrant Nigerian men living in the US and indigenous men from Nigeria: potential implications for prostate cancer risk reduction. J Immigr Minor Health. 2009 Oct.11(5):391-399. Pubmedid: 19225888.
    • Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea consumption and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jan.18(1):341-345. Pubmedid: 19124518. Pmcid: PMC3156033.
    • Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009 Feb.4 Suppl 1:S2. Pubmedid: 19208207. Pmcid: PMC2638461.
    • Reams RR, Agrawal D, Davis MB, Yoder S, Odedina FT, Kumar N, Higginbotham JM, Akinremi T, Suther S, Soliman KF. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer. 2009 Feb.4 Suppl 1:S3. Pubmedid: 19208208. Pmcid: PMC2638462.
    • Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, Courneya KS, Dryden T, Hanser S, Kumar N, Labriola D, Wardell DW, Sagar S. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009 Aug.7(3):85-120. Pubmedid: 19706235.
    • Odedina FT, Yu D, Akinremi TO, Reams RR, Freedman ML, Kumar N. Prostate cancer cognitive-behavioral factors in a West African population. J Immigr Minor Health. 2009 Aug.11(4):258-267. Pubmedid: 19051034.
    • Sellers TA, Vierkant RA, Djeu J, Celis E, Wang AH, Kumar N, Cerhan JR. Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control. 2008 Oct.19(8):805-811. Pubmedid: 18344007. Pmcid: PMC2575230.
    • Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol. 2008 Apr.1:1-14. Pubmedid: 20354574. Pmcid: PMC2846655.
    • Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol. 2008.6(1):29-36. Pubmedid: 18302908.
    • Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep.132(3 Suppl):340S-354S. Pubmedid: 17873179.
    • Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front Biosci (Landmark Ed). 2007 Jan.12:2309-2315. Pubmedid: 17127241.
    • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007.59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
    • Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005 Mar.14(3):656-661. Pubmedid: 15767346.
    • Kumar N, Riccardi D, Cantor A, Dalton K, Allen K. A case-control study evaluating the association of purposeful physical activity, body fat distribution, and steroid hormones on premenopausal breast cancer risk. Breast J. 2005 Jul.11(4):266-272. Pubmedid: 15982394.
    • Kumar N, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control. 2005 Jul.12(3):149-157. Pubmedid: 16062162.
    • Kumar N, Allen K, Riccardi D, Kazi A, Heine J. Isoflavones in breast cancer chemoprevention: where do we go from here?. Front Biosci (Landmark Ed). 2004 Sep.9:2927-2934. Pubmedid: 15353326.
    • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May.59(2):141-147. Pubmedid: 15042614.
    • Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev. 2004 May.62(5):204-211. Pubmedid: 15212320.
    • Kazi A, Wang Z, Kumar N, Falsetti S, Chan T, Dou Q. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 2004 Mar.24(2B):943-954. Pubmedid: 15161048.
    • Kumar N, Allen K, Riccardi D, Bercu B, Cantor A, Minton S, Balducci L, Jacobsen P. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?. Breast Cancer Res Treat. 2004 Jan.83(2):149-159. Pubmedid: 14997046.
    • Kumar N, Dalton K. Eicosapentaenoic acid: promising nutritional supplement in the treatment of cancer cachexia in elderly patients. J Evidence-Based Integrative Medicine. 2004.1(3):189-194. Pubmedid: noPMID.
    • Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003 Sep.66(6):965-976. Pubmedid: 12963483.
    • Kazi A, Urbizu D, Kuhn D, Acebo A, Jackson E, Greenfelder G, Kumar N, Dou Q. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med. 2003 Dec.12(6):879-887. Pubmedid: 14612961.
    • Kumar NB, Hopkins K, Allen K, Riccardi D, Besterman-Dahan K, Moyers S. Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice. Cancer Control. 2002 May.9(3):236-243. Pubmedid: 12060821.
    • Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002 Feb.94(4):1166-1174. Pubmedid: 11920488. Pmcid: PMC2377415.
    • Burns P, Kumar N. Alternative and complementary nutritional therapies in cancer prevention and treatment: implications in clinical practice. Nutrition. 2001 Mar.17(3):274-275. Pubmedid: 11312079.
    • Kumar N, Cantor A, Allen K, Cox C. Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span,and survival from breast carcinoma. Cancer. 2000 Jun.88(12):2751-2757. Pubmedid: 10870057.
    • Kumar N, Besterman-Dahan K. Nutrients in the Chemoprevention of Prostate Cancer: Current and Future Prospects. Cancer Control. 1999 Nov.6(6):580-586. Pubmedid: 10756389.
    • Kumar N, Allen K, Cantor A, Cox C, Greenberg H, Shah S, Lyman G. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?. Breast Cancer Res Treat. 1997 Jun.44(2):135-143. Pubmedid: 9232272.
    • Kumar N, Lyman G, Allan K, Cox C, Shapira D. Progressive weight gain in women and breast cancer risk: opportunity for breast cancer prevention. Cancer Detect Prev. 1996.20:510-510.
    • Kumar N, Lyman G, Allen K, Cox C, Schapira D. Timing of weight gain and breast cancer risk. Cancer. 1995 Jul.76(2):243-249. Pubmedid: 8625099.
    • Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM. Visceral obesity and breast cancer risk. Cancer. 1994 Jul.74(2):632-639. Pubmedid: 8033042.
    • Schapira D, Wolff P, Kumar N, Anderson J, Aziz N, Lyman G, Swanson M. The effect of weight loss on estimated breast cancer risk and sex hormone levels. Oncol Rep. 1994.1:613-617.
    • Kumar NB, Bostow DE, Schapira DV, Kritch KM. Efficacy of interactive, automated programmed instruction in nutrition education for cancer prevention. J Cancer Educ. 1993 Oct.8(3):203-211. Pubmedid: 8274368.
    • Schapira DV, Kumar NB, Lyman GH. Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. Cancer. 1993 May.71(9):2764-2768. Pubmedid: 8467456.
    • Schapira DV, Pamies RJ, Kumar NB, Herold AH, Van Durme DJ, Woodward LJ, Roetzheim RG. Cancer screening. Knowledge, recommendations, and practices of physicians. Cancer. 1993 Feb.71(3):839-843. Pubmedid: 8431866.
    • Schapira D, Kumar N, Lyman G. Body fat distribution and breast cancer risk within families. Cancer. 1993.70:2764-2768.
    • Schapira DV, Kumar NB, Clark RA, Yag C. Mammography screening credit card and compliance. Cancer. 1992 Jul.70(2):509-512. Pubmedid: 1617601.
    • Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS, LaPolla J. Upper-body fat distribution and endometrial cancer risk. Jama. 1991 Oct.266(13):1808-1811. Pubmedid: 1890709.
    • Schapira DV, Kumar NB, Lyman GH, Baile WF. The effect of duration of intervention and locus of control on dietary change. Am J Prev Med. 1991 Nov.7(6):341-347. Pubmedid: 1790041.
    • Schapira DV, Kumar NB, Lyman GH. Estimate of breast cancer risk reduction with weight loss. Cancer. 1991 May.67(10):2622-2625. Pubmedid: 2015563.
    • Schapira DV, Kumar NB, Lyman GH, Cox CE. Obesity and body fat distribution and breast cancer prognosis. Cancer. 1991 Jan.67(2):523-528. Pubmedid: 1985744.
    • Schapira DV, Kumar NB, Lyman GH. Obesity, body fat distribution, and sex hormones in breast cancer patients. Cancer. 1991 Apr.67(8):2215-2218. Pubmedid: 2004343.
    • Schapira DV, Kumar NB, Lyman GH. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat. 1990 Nov.17(1):3-7. Pubmedid: 2095926.
    • Schapira DV, Kumar NB, Lyman GH, Cox CE. Abdominal obesity and breast cancer risk. Ann Intern Med. 1990 Feb.112(3):182-186. Pubmedid: 2297194.
    • Schapira DV, Kumar NB. Disease prevention. A link missing. Arch Intern Med. 1989 Jun.149(6):1253-1254. Pubmedid: 2730245.
  • Grants

    • Title: Phase II Clinical Trial of GTC in Men on Active Surveillance
      Sponsor: Nat Institutes of Health
      PI: Kumar, N.

Find a Researcher Search